| Autor: |
Rohmann, Jessica L., Piccininni, Marco, Ebinger, Martin, Wendt, Matthias, Weber, Joachim E., Schwabauer, Eugen, Geisler, Frederik, Freitag, Erik, Harmel, Peter, Lorenz‐Meyer, Irina, Rohrpasser‐Napierkowski, Ira, Nolte, Christian H., Nabavi, Darius G., Schmehl, Ingo, Ekkernkamp, Axel, Endres, Matthias, Audebert, Heinrich J. |
| Předmět: |
|
| Zdroj: |
Annals of Neurology; Jan2023, Vol. 93 Issue 1, p50-63, 14p |
| Abstrakt: |
Objective: To determine the effect of additional mobile stroke unit (MSU) dispatch on functional outcomes among the full spectrum of stroke patients, regardless of subtype or potential contraindications to reperfusion therapies. Methods: We used data from the nonrandomized Berlin‐based B_PROUD study (02/2017 to 05/2019), in which MSUs were dispatched based solely on availability, and the linked B‐SPATIAL stroke registry. All patients with final stroke or transient ischemic attack (TIA) diagnoses were eligible. The intervention under study was the additional dispatch of an MSU, an emergency physician‐staffed ambulance equipped to provide prehospital imaging and thrombolytic treatment, compared to conventional ambulance alone. The primary outcome was the 3‐month modified Rankin Scale (mRS) score, and the co‐primary outcome was a 3‐tiered disability scale. We identified confounders using directed acyclic graphs and obtained adjusted effect estimates using inverse probability of treatment weighting. Results: MSUs were dispatched to 1,125 patients (mean age: 74 years, 46.5% female), while for 1,141 patients only conventional ambulances were dispatched (75 years, 49.9% female). After confounding adjustment, MSU dispatch was associated with more favorable 3‐month mRS scores (common odds ratio [cOR] = 0.82; 95% confidence interval [CI]: 0.71–0.94). No statistically significant association was found with the co‐primary outcome (cOR = 0.86; 9% CI: 0.72–1.01) or 7‐day mortality (OR = 0.94; 95% CI: 0.59–1.48). Interpretation: When considering the entire population of stroke/TIA patients, MSU dispatch improved 3‐month functional outcomes without evidence of compromised safety. Our results are relevant for decision‐makers since stroke subtype and treatment eligibility are unknown at time of dispatch. ANN NEUROL 2023;93:50–63 [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Plný text